Shots:
- Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future
- Additionally, Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration
- The collaboration will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel Ab-based therapy for diabetes
Click here to read full press release/ article | Ref: PRNewswire | Image: US News
The post Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes first appeared on PharmaShots.
